SpaceX Stock Has Pulled Back 39% From Its Peak and Could Be Worth as Little as $95 by 2028

SpaceX shares are down about 39% from their $225.64 all-time high and trade only ~3% above the ~$135 IPO price after a volatile post-IPO period. Even with consensus revenue growth to ~$105B in 2027 (from ~$45B this year, +141%), the article argues the current valuation already prices in substantial upside, with a bear case implying the stock could fall ~31% to ~$95 by 2028. A more realistic base case is ~$160 by 2028 (about +18%), suggesting modest long-term returns relative to investor expectations.

Analysis

The market is still pricing SPCX like a scarcity asset, not a normal growth equity. That matters because at this scale, incremental revenue is less important than whether the company can convert that growth into durable free cash flow without constant equity-like dilution or capex creep. If investors decide the business is moving from “infinite optionality” to “capital-intensive infrastructure,” the multiple can compress faster than revenue can expand.

The second-order risk is that the stock is now hostage to expectations management rather than operating execution. Any hiccup in launch cadence, customer concentration, regulatory timing, or monetization mix would hit the multiple first; the earnings line can lag the repricing by quarters. In that scenario, the loser is not just SPCX holders — it also tightens the valuation tape for adjacent high-duration names and any private-market space comp comp set.

Contrarian view: the consensus may be underestimating how long premium multiples can persist if the company keeps winning strategic contracts and remains the default platform in its niche. But the more relevant question is not whether the business grows, it’s whether growth outpaces the embedded valuation hurdle. On a 6-18 month horizon, the risk/reward still skews to de-rating unless there is visible evidence of recurring cash generation, not just top-line scale.

Key Decisions for Investors

• Fade strength in SPCX rather than chase weakness: if the name rallies back toward prior trading highs, consider initiating a short or put-spread position with a 3-6 month horizon. Thesis is multiple compression, not a business collapse; risk is capped if the stock re-rates on a credible cash-flow milestone.
• Use SPCX as a relative-value short against a profitable duration winner such as NVDA if you want growth exposure without paying the highest multiple in the tape. The pair benefits if the market shifts from story-stock enthusiasm to cash-flow discipline over the next 1-3 quarters.
• Do not add on dips until the company proves free-cash-flow conversion and capex intensity are stabilizing. The falsifier is a sustained beat-and-raise cycle with improving operating leverage; absent that, the stock remains vulnerable to valuation compression.
• Watch for secondary offerings, insider sales, or any update that implies dilution or a wider share base. Those events would be the cleanest catalyst for downside over a 1-3 month window.
• If you need to own secular growth, rotate preference toward NVDA/NFLX over SPCX on a risk-adjusted basis. Those names have clearer monetization and lower dependence on investors maintaining a quasi-private-market premium.